Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington's disease

  1. David Moreno-Delgado
  2. Mar Puigdellivol
  3. Estefanía Moreno
  4. Mar Rodríguez-Ruiz
  5. Joaquín Botta
  6. Paola Gasperini
  7. Anna Chiarlone
  8. Lesley A Howell
  9. Marco Scarselli
  10. Vicent Casadó
  11. Antoni Cortés
  12. Sergi Ferré
  13. Manuel Guzmán
  14. Carmen Lluís
  15. Jordi Alberch
  16. Enric I Canela
  17. Silvia Ginés  Is a corresponding author
  18. Peter J McCormick  Is a corresponding author
  1. University of Barcelona, Spain
  2. William Harvey Research Institute, Queen Mary University of London, United Kingdom
  3. University of Trento, Italy
  4. Instituto Ramon y Cajal de Investigacion Sanitaria, Universidad Complutense, Spain
  5. Queen Mary University of London, United Kingdom
  6. University of Pisa, Italy
  7. National Institutes of Health, United States

Abstract

Early Huntington's disease (HD) include over-activation of dopamine D1 receptors (D1R), producing an imbalance in dopaminergic neurotransmission and cell death. To reduce D1R over-activation, we present a strategy based on targeting complexes of D1R and histamine H3 receptors (H3R). Using an HD mouse striatal cell model and HD mouse organotypic brain slices we found that D1R-induced cell death signaling and neuronal degeneration, are mitigated by an H3R antagonist. We demonstrate that the D1R-H3R heteromer is expressed in HD mice at early but not late stages of HD, correlating with HD progression. In accordance, we found this target expressed in human control subjects and low-grade HD patients. Finally, treatment of HD mice with an H3R antagonist prevented cognitive and motor learning deficits and the loss of heteromer expression. Taken together, our results indicate that D1R - H3R heteromers play a pivotal role in dopamine signaling and represent novel targets for treating HD.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. David Moreno-Delgado

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  2. Mar Puigdellivol

    Biomedical Science, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Estefanía Moreno

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  4. Mar Rodríguez-Ruiz

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Joaquín Botta

    Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6450-1267
  6. Paola Gasperini

    CIBIO, University of Trento, Trento, Italy
    Competing interests
    The authors declare that no competing interests exist.
  7. Anna Chiarlone

    Deparment of Biochemistry and Molecular Biology, Instituto Ramon y Cajal de Investigacion Sanitaria, Universidad Complutense, Madrid, Spain
    Competing interests
    The authors declare that no competing interests exist.
  8. Lesley A Howell

    Chemistry, Queen Mary University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Marco Scarselli

    Pharmacology, University of Pisa, Pisa, Italy
    Competing interests
    The authors declare that no competing interests exist.
  10. Vicent Casadó

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  11. Antoni Cortés

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  12. Sergi Ferré

    NIDA, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Manuel Guzmán

    Deparment of Biochemistry and Molecular Biology, Instituto Ramon y Cajal de Investigacion Sanitaria, Universidad Complutense, Madrid, Spain
    Competing interests
    The authors declare that no competing interests exist.
  14. Carmen Lluís

    Biochemistry, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Jordi Alberch

    Biomedical Sciences, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8684-2721
  16. Enric I Canela

    Biochemistry and Molecular Bomedicine, University of Barcelona, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4992-7440
  17. Silvia Ginés

    Biomedical Science, University of Barcelona, Barcelona, Spain
    For correspondence
    silviagines@ub.edu
    Competing interests
    The authors declare that no competing interests exist.
  18. Peter J McCormick

    Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
    For correspondence
    p.mccormick@qmul.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2225-5181

Funding

BBSRC CASE (MCCORMICK_U15BB)

  • Peter J McCormick

RSC Grant Project (RG140118)

  • Peter J McCormick

BBSRC (BB/N504282/3)

  • Peter J McCormick

Ministerio de Economia y Competitividad (RTI2018-094374-B-I00)

  • Silvia Ginés

Fundació la Marató de TV3 (20140610)

  • Enric I Canela

Jerome LeJeune Foundation (FJL-01/01/2013)

  • Peter J McCormick

Ministerio de Economia y Competitividad (SAF2017-88076-R)

  • Jordi Alberch

Ministerio de Economia y Competitividad (RTI2018-095311-B-I00)

  • Manuel Guzmán

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures involving animals were performed in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and approved by the local animal care committee of the Universitat de Barcelona (99/01) and Generalitat de Catalunya (99/1094), in accordance with the European (2010/63/EU) and Spanish (RD53/2013) regulations for the care and use of laboratory animals. All protocols involving postmortem human sample were approved by the institutional ethic committees.

Copyright

© 2020, Moreno-Delgado et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

Share this article

https://doi.org/10.7554/eLife.51093

Further reading

    1. Neuroscience
    Sven Ohl, Martin Rolfs
    Research Article

    Detecting causal relations structures our perception of events in the world. Here, we determined for visual interactions whether generalized (i.e. feature-invariant) or specialized (i.e. feature-selective) visual routines underlie the perception of causality. To this end, we applied a visual adaptation protocol to assess the adaptability of specific features in classical launching events of simple geometric shapes. We asked observers to report whether they observed a launch or a pass in ambiguous test events (i.e. the overlap between two discs varied from trial to trial). After prolonged exposure to causal launch events (the adaptor) defined by a particular set of features (i.e. a particular motion direction, motion speed, or feature conjunction), observers were less likely to see causal launches in subsequent ambiguous test events than before adaptation. Crucially, adaptation was contingent on the causal impression in launches as demonstrated by a lack of adaptation in non-causal control events. We assessed whether this negative aftereffect transfers to test events with a new set of feature values that were not presented during adaptation. Processing in specialized (as opposed to generalized) visual routines predicts that the transfer of visual adaptation depends on the feature similarity of the adaptor and the test event. We show that the negative aftereffects do not transfer to unadapted launch directions but do transfer to launch events of different speeds. Finally, we used colored discs to assign distinct feature-based identities to the launching and the launched stimulus. We found that the adaptation transferred across colors if the test event had the same motion direction as the adaptor. In summary, visual adaptation allowed us to carve out a visual feature space underlying the perception of causality and revealed specialized visual routines that are tuned to a launch’s motion direction.

    1. Neuroscience
    Ulrike Pech, Jasper Janssens ... Patrik Verstreken
    Research Article

    The classical diagnosis of Parkinsonism is based on motor symptoms that are the consequence of nigrostriatal pathway dysfunction and reduced dopaminergic output. However, a decade prior to the emergence of motor issues, patients frequently experience non-motor symptoms, such as a reduced sense of smell (hyposmia). The cellular and molecular bases for these early defects remain enigmatic. To explore this, we developed a new collection of five fruit fly models of familial Parkinsonism and conducted single-cell RNA sequencing on young brains of these models. Interestingly, cholinergic projection neurons are the most vulnerable cells, and genes associated with presynaptic function are the most deregulated. Additional single nucleus sequencing of three specific brain regions of Parkinson’s disease patients confirms these findings. Indeed, the disturbances lead to early synaptic dysfunction, notably affecting cholinergic olfactory projection neurons crucial for olfactory function in flies. Correcting these defects specifically in olfactory cholinergic interneurons in flies or inducing cholinergic signaling in Parkinson mutant human induced dopaminergic neurons in vitro using nicotine, both rescue age-dependent dopaminergic neuron decline. Hence, our research uncovers that one of the earliest indicators of disease in five different models of familial Parkinsonism is synaptic dysfunction in higher-order cholinergic projection neurons and this contributes to the development of hyposmia. Furthermore, the shared pathways of synaptic failure in these cholinergic neurons ultimately contribute to dopaminergic dysfunction later in life.